Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer

International Journal of Nanomedicine

Volumn 6, Issue 1, 2011, Pages 59-69

  Liu, Jianfeng ^a,b,c   Liu, Jinjian ^b   Chu, Liping ^b   Wang, Yanming ^a   Duan, Yajun ^a   Feng, Lina ^b   Yang, Cuihong ^a   Wang, Ling ^a   Kong, Deling ^a  

^a NANKAI UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

In vivo phage display; Nonsmall cell lung cancer; Peptide; Polyamidoamine dendrimer; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLCYSTYLPROLYLLEUCYLSERYLHISTIDYLSERYLLEUCYLISOLEUCYLCYSTYLTYROSINE; DENDRIMER; DRUG CARRIER; POLYAMIDOAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; DOSE RESPONSE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; PEPTIDES; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79251492029     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14601     Document Type: Article

References (45)

1. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: Principles and practice. Br J Cancer. 2008(3);99:392-397.
2. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimermediated solubilization: Formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm. 2009;6(3):940-950.
3. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomed. 2008;3(5):679-702.
4. Patil ML, Zhang M, Betigeri S, Taratula O, He H, Minko T. Surfacemodified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem. 2008;19(7):1396-1403.
5. Kaminskas LM, Kelly BD, McLeod VM, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm. 2009;6(4):1190-1204.
6. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine. 2010;5:101-108.
7. Gaucher G, Marchessault RH, Leroux JC. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release.2010;143(1):2-12.
8. Matsumoto S, Christie RJ, Nishiyama N, et al. Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules. 2009;10(1):119-127.
9. Samad A, Alam MI, Saxena K. Dendrimers: A class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des. 2009;15(25):2958-2969.
10. Shukla R, Thomas TP, Peters JL, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem.2006;17(5):1109-1115.
11. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem. 2008;19(11): 2239-2252.
12. Swanson SD, Kukowska-Latallo JF, Patri AK, et al. Targeted gadoliniumloaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine. 2008;3(2):201-210.
13. Yang W, Cheng Y, Xu T, Wang X, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2009;44(2):862-868.
14. Yang H, Kao WJ. Synthesis and characterization of nanoscale dendritic RGD clusters for potential applications in tissue engineering and drug delivery. Int J Nanomedicine. 2007;2(1):89-99.
15. Boswell CA, Eck PK, Regino CA, et al. Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm. 2008;5(4):527-539.
16. Hill E, Shukla R, Park SS, Baker JR Jr. Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures. Bioconjug Chem. 2007;18(6):1756-1762.
17. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res.2007;67(22):10958-10965.
18. Chabre YM, Roy R. Recent trends in glycodendrimer syntheses and applications. Curr Top Med Chem. 2008;8(14):1237-1285.
19. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm.2005;295(1-2):221-233.
20. Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptorpositive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther. 2006;5(1):52-59.
21. Kurtoglu YE, Mishra MK, Kannan S, Kannan RM. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm. 2010;384(1-2):189-194.
22. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1-7.
23. Smith GP. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705): 1315-1317.
24. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science. 1990;249(4967):386-390.
25. Hui X, Han Y, Liang S, et al. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release. 2008;131(2):86-93.
26. Yang W, Luo D, Wang S, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res. 2008;14(17): 5494-5502.
27. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380(6572):364-366.
28. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15(6): 542-546.
29. Howell RC, Revskaya E, Pazo V, Nosanchuk JD, Casadevall A, Dadachova E. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug Chem. 2007;18(6):1739-1748.
30. Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res.2005;11(1):139-146.
31. Zitzmann S, Krämer S, Mier W, et al. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. J Nucl Med. 2007;48(6): 965-972.
32. Chen B, Cao S, Zhang Y, et al. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol. 2009;10:63.
33. Wu X, Yan Q, Huang Y, et al. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 2010; 14(1-2):351-356.
34. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8(7):751-755.
35. Lesniak WG, Kariapper MS, Nair BM, et al. Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjug Chem. 2007;18(4): 1148-1154.
36. Thannhauser TW, Konishi Y, Scheraga HA. Analysis for disulfide bonds in peptides and proteins. Methods Enzymol. 1987;143:115-119.
37. Lee G, Ge B. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomark.2009;5(4):177-188.
38. Pakkala M, Hekim C, Soininen P, et al. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J Pept Sci. 2007; 13(5):348-353.
39. Malik N, Wiwattanapatapee R, Klopsch R, et al. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65(1-2):133-148.
40. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem. 2008;19(11): 2239-2252.
41. Toshinari T, Eiji Y, Chie K, Atsushi H, Kenji K. Synthesis of a polyamidoamine dendron-bearing lipid having sugar moieties and its use for preparation of nonviral gene vectors. Res Chem Intermed. 2009;35(8-9): 1005-1014.
42. Duan Y, Yang C, Zhang Z, Liu J, Zheng J, Kong D. Poly(ethylene glycol)-grafted polyethylenamine modified with G250 monoclonal antibody for tumor gene therapy. Hum Gene Ther. 2010;21(2): 191-208.
43. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR Jr. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb). 2005;14(46):5739-5741.
44. Sarin H, Kanevsky AS, Wu H, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med. 2008;6:80.
45. Prieto MJ, Schilrreff P, Tesoriero MV, Morilla MJ, Romero EL. Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. Int J Pharm. 2008;360(1-2):204-212.